Tufts CSDD Suggest Old Habits Affecting Strategic Partnerships
Despite the fact that a growing number of developers and CROs have now had three to five years of experience with these strategic relationships, speed and efficiency improvements and cost savings remain the exception.
"Despite the fact that a growing number of developers and CROs have now had three to five years of experience with these strategic relationships, speed and efficiency improvements and cost savings remain the exception," said Ken Getz, associate professor and director of sponsored research at Tufts CSDD in response to its most recent management report. And while strategic relationships between drug developers and contract research organizations(CROs) are generating innovative approaches to clinical trial design and execution, Getz added, "Old habits are slow to change and most drug developers are supporting practices that prevent them from integrating their strategic relationships and leveraging the value of these important collaborative models."
The study also found:
- Companies use a mix of outsourcing relationship models simultaneously on a per-study basis, including strategic and transactional relationships, along with in-house resources.
- Nearly all clinical studies outsourced site monitoring, and, in an overwhelming majority of studies, site identification and selection.
- In more than 70% of clinical studies, data management, medical monitoring, patient recruitment and retention, and statistical analyses were outsourced.
- For studies that were strategically outsourced, screen failure rates were higher and the frequency of protocol amendments was lower.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
